WTA introduces mandatory biological sex testing for all female players

The Women’s Tennis Association (WTA) announced a new eligibility policy that takes effect on 21 July. All players on the WTA Tour must undergo a one‑time test to confirm the presence of the SRY gene, using a cheek swab, blood or saliva sample, in order to verify biological sex. The rule bars transgender women from competing and replaces earlier provisions that allowed participation if testosterone levels were below a set threshold for two years. The WTA says the measure is intended to preserve the integrity and fairness of professional women’s tennis. Similar mandatory testing has already been adopted by boxing and athletics bodies, prompting criticism and debate over the scientific adequacy of the SRY test and its impact on athletes’ rights. The association’s statement acknowledges the sensitivity of the issue and pledges respectful implementation. The policy has generated public reaction, including comments from Wimbledon champion Linda Noskova, whose image was used in media coverage, and scrutiny from scientists who question whether the SRY gene alone can determine sex, as well as broader discussion among fans and officials.